Recent research confirms TDP-43 aggregation in vascular dementia, with advancements in biomarkers and therapies highlighting potential for early intervention and personalized prevention. New studies r...
The cGAS-STING pathway, crucial for innate immunity, drives harmful neuroinflammation in aging and Alzheimer’s, with recent studies highlighting therapeutic challenges and biomarker potential fo...
Recent studies validate blood biomarkers like p-tau217 for predicting Alzheimer’s onset within 3-4 years at 94% accuracy, enabling early interventions but raising ethical and socioeconomic conce...
Analytical post exploring CAR-T cell therapy’s potential to treat Alzheimer’s by targeting amyloid plaques, with insights from recent clinical trials and cost-benefit considerations. Innov...
Recent studies reveal CAR-T cells with lecanemab antibodies reduce amyloid plaques in mice, highlighting a shift towards personalized cell-based therapies for Alzheimer’s treatment. New research...
Emerging research identifies mitochondrial dysfunction as a critical factor in Alzheimer’s disease, with new therapies and lifestyle interventions offering hope for early intervention and improv...
Recent studies reveal that age-related proteasomal decline activates the cGAS-STING pathway through mitochondrial DNA leakage, fueling chronic inflammation linked to Alzheimer’s, with exercise a...
Recent studies reveal UBQLN2’s role in accelerating α-synuclein aggregation through liquid-liquid phase separation, offering new therapeutic targets for Parkinson’s disease and related ne...
The shift from stem cell transplants to extracellular vesicles offers enhanced stability, easier storage, and scalable production, potentially improving treatment accessibility for conditions like Alz...
Extracellular vesicles from stem cells offer a safer alternative to transplants for Alzheimer’s and Parkinson’s, reducing neuroinflammation and promoting repair with promising preclinical ...
